Photodynamic Therapy With LUZ11 in Advanced Head and Neck Cancer

NCT02070432 ↗

Phase 1/2 Unknown 20 enrolled Luzitin SA

NaSingle-groupOpen-labelTreatment

Summary

This study will investigate the tolerability, recommended dose and pharmacokinetics of LUZ11 following photodynamic therapy (PDT) of patients with advanced head and neck cancer.

Timeline

Start: 2014-02
Primary completion: 2016-07
Completion: 2016-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LUZ11	Other / unclassified	—	Intravenous

Photodynamic Therapy With LUZ11 in Advanced Head and Neck Cancer

Summary

Timeline

Drugs

Indications